Italy Is Southern Europe’s Leading Clinical Research Market

Italy is one of Europe’s most established clinical trial markets.

With a population of 58.9 million, more than 8,000 trials listed on ClinicalTrials.gov and a national network of more than 50 IRCCS research hospitals, Italy offers sponsors scale, investigator quality and deep institutional research infrastructure.

Its strongest advantage is research density. Milan, Rome, Padua, Bologna, Florence, Genoa, Naples and Turin all contribute to a broad national site network, with especially strong depth in oncology, cardiovascular disease, neuroscience, rare disease, hematology and hepatology.

Italy’s IRCCS system gives the country a unique research structure within Europe, combining specialist hospitals, dedicated public research funding and long term investigator pipelines across major therapeutic areas.

For sponsors, Italy is not just a Southern European market. It is a high credibility research destination where academic depth, patient access and therapeutic specialization can strengthen Phase I to Phase IV programs.